10P Prediction of the 21-gene recurrence score by a non-genomic approach in stage I estrogen receptor-positive, HER2-negative breast cancer

Abstract

The recurrence score (RS), which is derived from the results of an assay of 21 genes, predicts the likelihood of recurrence in patients with breast cancer, thus potentially helping clinicians decide when to recommend chemotherapy. However, non-genomic clinicopathologic prognostic markers may also be able to distinguish patients with low, intermediate, and high risk of recurrence without the added cost of genetic testing.